Cleveland Clinic Florida, Weston, FL
Carlos Rivera , Iktej Singh Jabbal , Marita Yaghi , Kevin Scott Landau , Nicolas Muruve , Diana Saravia , Tiffany L. George , Zeina A. Nahleh , Rafael Arteta-Bulos
Background: Localized muscle invasive bladder cancer carries a significant recurrence and mortality rate. The purpose of this study was to compare 5-year overall survival (OS) of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC), RC alone, bladder preserving chemoradiotherapy (BPCRT) and radiation alone (RT) on selected histologies. Methods: We sampled the National Cancer Database (NCDB) for bladder cancer patients diagnosed with AJCC 7th Stage 2 and 3 for urothelial carcinoma (UC) including variant histologies, squamous cell carcinoma (SCC) and adenocarcinoma (AC) from 2004-2018 with definitive intent treatment. 5-year Kaplan-Meier survival plots were utilized to assess survival differences amongst treatment modalities and stratified by selected histologies. Multivariate cox regression models were used to compare hazard ratios and logistic regression analysis was performed for covariate analysis. A p-value <0.05 was considered statistically significant. Results: A total of 20,629 patients met inclusion criteria. The average age was 69.51 + 11.02 years, 68% were male. UC represented 94.1% of selected histologies, followed by 4.6% SCC and 1.3% AC. For all combined histologies, 5-year OS for patients with NAC followed by RC was 58%, 48% for RC alone, 33% for BPCRT and 10% for RT alone. RC alone provided a longer OS in the SCC and AC groups, 48% and 47% respectively (p<0.001). NAC followed by RC showed superior OS in the UC group (58%, p<0.001), with OS decreasing to 43% in SCC and 44% in AC. BPCRT showed lower 5-year OS in all selected histologies when compared to NAC followed by RC and RC alone (33% in UC, 27% in SCC and 24% in AC group). In all selected histologies, RT showed the lowest 5-year OS (10% in UC, 8% in SCC and 17% in AC group; p<0.001). Furthermore, covariables associated with lower 5-year survival were male sex (p<0.001) and TNM Stage 3 (p<0.001). Conclusions: NAC followed by RC showed improved 5-year OS for UC. The benefit of NAC was marginal for SCC and AC histology. RC is better than BPCRT for all histologies. RT alone showed inferior 5-year OS for all histologies.
Treatment Patients N = 20629 | Urothelial Carcinoma Histology N (%) | Squamous Cell Carcinoma Histology N (%) | Adenocarcinoma Histology N (%) | Odd Ratio (CI) | Hazard Ratio (CI) | p-value |
---|---|---|---|---|---|---|
NAC followed by RC | 5117 (26.4) | 104 (10.9) | 40 (14.9) | 1 | - | |
RC Alone | 8250 (42.5) | 658 (69.2) | 161 (59.9) | 1.45 (1.38-1.52) | < 0.001 | |
BPRCT | 5806 (29.9) | 156 (16.4) | 62 (23.0) | 2.02 (1.92-2.13) | < 0.001 | |
RT Alone | 236 (1.2) | 33 (3.5) | 6 (2.2) | 5.21 (4.57-5.94) | < 0.001 | |
Charlson Deyo Score (CDS = 0) | 66.9% (n=13811) | 1 | - | |||
CDS = 1 | 21.8% (n=4501) | 1.87 (1.60 - 2.19) | < 0.001 | |||
CDS = 2 | 7.6% (n=1572) | 1.24 (1.05 - 1.46) | <0.01 | |||
TNM Stage 2 | 82.8% (n=17076) | 1 | -- | |||
TNM Stage 3 | 17.2% (n=3553) | 1.67 (1.55 - 1.81) | < 0.001 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Minit Jalan Shah
2023 ASCO Annual Meeting
First Author: Yicong Chen
2024 ASCO Genitourinary Cancers Symposium
First Author: Prantik Das
2021 Genitourinary Cancers Symposium
First Author: Benjamin Walker Fischer-Valuck